Cell-Cell Interactions are essential for multiple biological processes to run smoothly, including a variety of processes like embryonic development, immunity, and neuronal signaling. Cell-cell interaction dynamics can be monitored in vivo by using intravital microscopy, but this approach does not provide any information regarding the ligands and receptors involved or enable the isolation of interacting cells for downstream analysis. Now a complementary approach has come into the scene that uses bacterial sortase A-mediated cell labeling across synapses of immune cells to identify receptor-ligand interactions between cells in living mice. It works by generating a signal that can subsequently be detected ex vivo by flow cytometry. This approach for the labeling of ‘kiss-and-run’ interactions between immune cells is known as ‘Labelling Immune Partnerships by SorTagging Intercellular Contacts’ (LIPSTIC). Using LIPSTIC, scientists have shown that the interactions between dendritic cells and CD4+ T cells during T-cell priming in vivo occur in two distinct modalities. These two modalities are early, cognate stage, during which CD40–CD40L interactions occur specifically between T cells and antigen-loaded dendritic cells; and a later, non-cognate stage during which these interactions no longer require the prior engagement of T-cell receptor. Therefore, LIPSTIC enables the direct measurement of cell-cell interaction dynamics both in vitro and in vivo. Given the flexibility for use of this technique with different receptor-ligand pairs and a range of detectable labels, Scientists expect that this approach will be of use to any field of biology requiring quantification of intercellular communication.
DelveInsight Blog
Related Article
Xtant Medical’s SimipliGraft TM and SimpliMaxTM Launch; Perelel’s Fertility Support Products Expansion; Medtronic’s InceptivTM FDA Approval; GE Healthcare’s Vital Signs Monitor FDA 510(K) Clearance; Merck’s Pneumonia Vaccine Positive Results; Artivion’s Aortic Devices AATS Win
Xtant Medical Announced the Launch of SimipliGraft TM and SimpliMaxTM for Chronic and Acute Wounds On April 30, 2024, Xtant Medical Holdings, Inc., a global medical technology firm specializing in surgical remedies for spinal disorders, announced the complete commercial availability of two amniotic membran...
Find MoreX4 Pharmaceuticals’ XOLREMDI FDA Approval; ONO to Acquire Deciphera Pharmaceuticals; Johnson & Johnson’s SIRTURO CHMP Approval; BeiGene’s Tislelizumab EC Approval; Sanofi’s Rilzabrutinib LUNA 3 Phase III Trial
FDA Greenlights XOLREMDI Capsules from X4 Pharmaceuticals for WHIM Syndrome Treatment X4 Pharmaceuticals has declared that the FDA has granted approval for XOLREMDI™ (mavorixafor) capsules to be utilized in individuals aged 12 and above who have WHIM syndrome (characterized by warts, hypogammaglobulinemia, infec...
Find MoreIpsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.